BioNano Genomics Inc vs DENTSPLY SIRONA Inc — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while DENTSPLY SIRONA Inc trades at $13.27 (market cap $2.55B). The key difference: DENTSPLY SIRONA Inc is far larger — about 193.2× BioNano Genomics Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | XRAY | |
|---|---|---|
Market Cap | $13.20M | $2.55B |
Sector | Health | Health |
52-Week High | $4.92 | $16.85 |
52-Week Low | $1.09 | $9.64 |
Enterprise Value | $15.81M | $4.69B |
Dividend Yield | — | 5.04% |
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Dentsply Sirona (XRAY) trades at $12.78, up 4.24% today, with technical indicators showing bullish momentum despite recent earnings misses. The company faces fundamental challenges with negative net income margins (-17.06%) and declining revenue trends, though it maintains a solid gross margin of 48.93%. Recent developments include new CFO appointment and expanded distribution partnerships, while analyst consensus remains mixed with a $13.33 price target.
The stock presents a turnaround opportunity with improving cash flow trends and strategic initiatives, but faces significant execution risks amid persistent profitability challenges. Near-term catalysts include Q2 2026 earnings and continued progress on the Return-to-Growth plan, though high debt levels and competitive pressures warrant caution for investors.
Trailing returns across standard periods
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →